Cytoreductive Surgery Plus HIPEC for Patients With Gastric Cancers That Have Limited Peritoneal Carcinomatosis
At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Nataliya Uboha, MD, PhD, University of Wisconsin, Milwaukee, Wisconsin, discusses the role cytoreductive surgery with HIPEC has for patients with gastric cancers that have peritoneal carcinomatosis.
Transcript:
I'm Nataliya Uboha, I'm a medical oncologist specializing in treating patients with gastrointestinal cancers. I practice at the University of Wisconsin and today I participated in the debate about the use of cytoreductive surgery (CRS) with HIPEC in patients with gastric cancer that have peritoneal carcinomatosis.
Patients with peritoneal carcinomatosis from gastric cancer have poor prognosis, they don't respond well to systemic therapy so this is an area of ongoing exploration and research of how to best treat these patients and cytoreductive surgery and HIPEC have been under investigation for years.
At this time, we don't have any prospective data supporting the use of CRS or HIPEC in these patients however, there are some that potentially benefit from this so I think clinical trial enrollment is appropriate for these patients but outside of clinical trials, these types of approaches should not be utilized in standard clinical setting.
Source:
Uboha N. Debate: Management of Gastric Cancer With Limited Peritoneal Carcinomatosis - Cytoreduction and HIPEC for All: Yes vs No. Presented at Great Debates and Updates in Gastrointestinal Malignancies. May 17-18, 2024. New York, NY.
